Pertussis toxin prevents presynaptic inhibition by kainate receptors of rat hippocampal [3H]GABA release by A. Cunha, Rodrigo et al.
Pertussis toxin prevents presynaptic inhibition by kainate receptors of rat
hippocampal [3H]GABA release
Rodrigo A. Cunhaa;b;*, Joa‹o O. Malvac, J.A. Ribeiroa
aLaboratory of Neurosciences, Faculty of Medicine, University of Lisbon, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal
bDepartment of Chemistry and Biochemistry, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal
cDepartment of Biochemistry, Faculty of Medicine and Center for Neurosciences of Coimbra, University of Coimbra, 3000 Coimbra, Portugal
Received 7 December 1999; received in revised form 8 February 2000
Edited by Jesus Avila
Abstract Kainate receptors are ionotropic receptors, also
reported to couple to Gi/Go proteins, increasing neuronal
excitability through disinhibition of neuronal circuits. We
directly tested in hippocampal synaptosomes if kainate recep-
tor-mediated inhibition of GABA release involved a metabotropic
action. The kainate analogue, domoate (3 WM), inhibited by 24%
[3H]GABA-evoked release, an effect reduced by 76% in
synaptosomes pre-treated with pertussis toxin. Protein kinase
C inhibition attenuated by 82% domoate-induced inhibition of
GABA release whereas protein kinase C activation did not
change kainate receptor binding. Thus, domoate inhibition of
GABA release recruits Gi/Go proteins and a protein kinase C
pathway.
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1. Introduction
Kainate receptors are a subtype of ionotropic glutamate
receptors abundantly expressed in the hippocampus, but their
physiological function is only now beginning to emerge [1].
The over-stimulation of kainate receptors leads to epilepti-
form activity and has proven to be a valuable experimental
animal model of temporal lobe epilepsy [2]. One proposed
mechanism of kainate-induced epileptogenesis is the disrup-
tion of GABAergic transmission [1], which was found in elec-
trophysiological recordings of hippocampal synaptic transmis-
sion to involve a metabotropic action of kainate receptors [3].
However, electrophysiological approaches have not unambig-
uously resolved if kainate receptors presynaptically inhibit
GABA release [4] or if dendritic kainate receptors cause a
sustained depolarization of GABAergic interneurons indi-
rectly decreasing evoked GABAergic transmission [5]. In
such situations where both somatic and presynaptic receptors
contribute to a response, electrophysiological approaches have
to rely on miniature potential analysis to indirectly study the
mechanisms of presynaptic inhibition. However, there are pre-
vious examples of presynaptic modulators, such as adenosine,
that a¡ect spontaneous and evoked release of neurotransmit-
ters via di¡erent mechanisms (discussed in [6]). An alternative
is to use an experimental model ideally suited to study the
presynaptic modulation of neurotransmitter release, the syn-
aptosomes [7]. Thus, we now directly tested if kainate receptor
inhibition of GABA release from hippocampal synaptosomes
[8] depends on protein G activation and on protein kinase
activities, with care to distinguish if the protein kinases par-
ticipated on the kainate receptor transducing pathway or were
modulating kainate receptor function.
2. Materials and methods
Domoic acid, phorbol-12,13-didecanoate and 4K-phorbol-12,13-di-
decanoate were from RBI, (RS)-K-methyl-4-phosphonophenylglycine
(MPPG), (S)-K-methyl-4-carboxyphenylglycine (MCPG) and [3H](2S,
4R)-4-methylglutamate (MGA) were from Tocris Cookson, pertussis
toxin, chelerythrine, KN-62, HA-1004, H-89 and PD 98059 were from
Calbiochem, Q-amino-n-butyric acid (GABA), aminooxyacetic acid,
nipecotic acid and 8-bromo-cAMP were from Sigma, CGP 55845
was from Ciba Geigy and [3H]GABA was from Amersham.
[3H]GABA release experiments were performed as previously de-
scribed [8] using hippocampal synaptosomes, obtained from halo-
thane-anesthetized male Wistar rats (6^8 weeks old), by sucrose/Per-
coll isopycnic centrifugations. Brie£y, synaptosomes were loaded with
[3H]GABA (1.5 WCi/ml, 1.875 nM) together with 6 nM unlabelled
GABA for 30 min in Krebs solution, gassed with a 95% O2 and 5%
CO2 mixture, of the following composition: 124 mM NaCl, 3 mM
KCl, 1.25 mM KH2PO4, 1 mM MgSO4, 2 mM CaCl2, 26 mM
NaHCO3, 10 mM glucose, 0.1 mM aminooxoacetic acid, pH 7.4.
After loading, the synaptosomes were washed in gassed Krebs solu-
tion containing nipecotic acid (1 WM), which was present in all super-
fusion solutions. The synaptosomes were then layered over Whatman
GF/C ¢lters in 90 Wl chambers and superfused with gassed Krebs
solution with a £ow rate of 0.6 ml/min. After 45-min washing, e¥uent
samples were collected in 3-min fractions and 500 Wl were used for
scintillation counting. The synaptosomes were stimulated twice for
2 min with an isomolar substitution of Na by K (20 mM) 4 min
(S1) and 22 min (S2) after starting sample collection. Under these
conditions, K-evoked tritium release is mostly Ca2-dependent and
is mainly due to [3H]GABA release [8], allowing measurement of the
evoked [3H]GABA release as evoked tritium release [8,9]. The e¡ect of
tested drugs, added to the perfusion medium 6 min before S2, was
evaluated by modi¢cation of tritium release in S2/S1. When we eval-
uated the modi¢cations of the e¡ect of domoic acid by other drugs,
these drugs were applied 15 min before starting sample collection and
hence were present during S1 and S2. When present during S1 and S2,
MPPG plus MCPG, CGP 55845 or any of the tested protein kinase
modulators (chelerythrine, HA-1004, H-89, KN-62, PD 98059, phor-
bol-12,13-didecanoate and 4K-phorbol-12,13-didecanoate) did not sig-
ni¢cantly alter (Ps 0.05) the S2/S1 as compared to the S2/S1 ratio
obtained in the absence of drugs (data not shown). When the in£u-
ence of pertussis toxin pre-treatment on the e¡ect of tested drugs on
[3H]GABA release was investigated, the synaptosomes were treated
for 2 h with 2 Wg/ml of activated pertussis toxin at 37‡C (see [10]),
before labelling with [3H]GABA. A parallel aliquot of the same syn-
aptosomal batch was always incubated for 2 h with Krebs solution, to
control for the in£uence of the 2 h incubation period on the e¡ect of
drugs on [3H]GABA release.
[3H]MGA saturation curves were performed in rat hippocampal
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synaptosomal membranes, as described in [10]. Before preparation of
the membranes, the synaptosomes were incubated for 15 min at 37‡C
without or with either the protein kinase A activator, 8-bromo-cAMP
(1 mM), or with the protein kinase C activator, phorbol-12,13-dide-
canoate (250 nM), as described [11].
The values are presented as mean þ S.E.M. To test the signi¢cance
of the e¡ect of a drug versus control, a paired Student’s t-test was
used. When making comparisons from a di¡erent set of experiments
with control, one way analysis of variance (ANOVA) was used, fol-
lowed by Dunnett’s test. P90.05 was considered to represent a sig-
ni¢cant di¡erence.
3. Results and discussion
Since hippocampal kainate receptors can couple to Gi/Go
proteins [10] and pertussis toxin (PTx) attenuates kainate re-
ceptor-mediated inhibition of GABAergic transmission [3], we
now tested the e¡ect of PTx pre-treatment directly on
[3H]GABA release from superfused hippocampal synapto-
somes. Pre-treatment of the synaptosomes with PTx (2 Wg/
ml) for 2 h at 37‡C did not change the loading with
[3H]GABA and the basal and evoked release of tritium (see
Fig. 1). To test the e¡ectiveness of this PTx pre-treatment to
inactivate Gi/Go proteins, we ¢rst tested the e¡ect of PTx
treatment on the inhibitory e¡ect of GABAB receptors that
are coupled to Gi/Go proteins in hippocampal GABAergic
nerve terminals [12]. The GABA receptor agonist, muscimol
(10 WM), inhibited the evoked release of [3H]GABA by
34 þ 4% (n = 4) from control synaptosomes (Fig. 1A) and
this e¡ect was fully prevented by CGP 55485 (1 WM, present
during S1 and S2, n = 3, Fig. 1B) indicating the involvement of
GABAB receptors. In PTx-treated synaptosomes (Fig. 1B),
the inhibitory e¡ect of muscimol (10 WM) was attenuated by
81 þ 6% (n = 4) compared to control synaptosomes, con¢rming
that PTx treatment attenuates responses involving Gi/Go pro-
teins. The kainate receptor agonist, domoate (3 WM) caused a
24 þ 3% inhibition (n = 4) of the evoked release of [3H]GABA
from control synaptosomes (Fig. 1C), an e¡ect previously
shown to be antagonized by the non-NMDA ionotropic glu-
tamate receptor antagonist, CNQX (10 WM) and by the
GluR6 antagonist, NS-102 (1 WM), i.e. involving the activa-
tion of pharmacologically de¢ned kainate receptors, possibly
of the GluR6 subtype [8]. In PTx-treated synaptosomes, do-
moate only caused a 6 þ 1% inhibition of the evoked release of
[3H]GABA (n = 4) (Fig. 1D). These results indicate that kai-
nate receptor-mediated inhibition of [3H]GABA-evoked re-
lease depends on the presence of functional Gi/Go proteins.
We also excluded the unlikely possibility that activation of
GABAB receptors might mediate domoate inhibition of
GABA release, since CGP 55485 (1 WM) did not signi¢cantly
(Ps 0.05) modify the inhibition by domoate (3 WM) of
[3H]GABA-evoked release (Fig. 1D).
One aspect that remained to be ruled out was the possible
direct activation of metabotropic glutamate receptors by do-
moic acid. The simultaneous presence of the group I and II
antagonist, (S)-K-methyl-4-carboxyphenylglycine (500 WM),
Fig. 1. Inhibition by the GABAB receptor agonist, muscimol, and by the kainate receptor agonist, domoate, of GABA release from rat hippo-
campal synaptosomes is sensitive to pertussis toxin. In (A) and (C) the time course of [3H]GABA release is shown. The preparation was chal-
lenged with two periods of stimulation with 20 mM K (S1 and S2), as indicated by the bars above the abscissa. The open symbols represent
tritium release from a control chamber, to which no drug was added, and the ¢lled symbols represent the tritium release of the test chamber,
to which either muscimol (10 WM; in A) or domoate (3 WM; in C) was added through the superfusate, as indicated by the upper bar. In (B)
and (D) it is shown that pre-treatment of the synaptosomes with activated pertussis toxin (2 Wg/ml) attenuated the inhibitory e¡ect of muscimol
(10 WM; in B) and of domoate (3 WM; in D). The results are mean þ S.E.M. of four experiments. *P6 0.05 versus the inhibitory e¡ect of mus-
cimol (10 WM; in B) or of domoate (3 WM; in C) in control synaptosomes (¢rst column).
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and of the group II and III antagonist, (RS)-K-methyl-4-phos-
phonophenylglycine (1 mM), did not attenuate the domoate
(3 WM)-induced inhibition of [3H]GABA evoked release,
which was 21 þ 2% in the absence and 26 þ 4% in the presence
of the metabotropic receptor antagonists (n = 3). Thus, it is
unlikely that metabotropic glutamate receptor activation may
be responsible for the domoic acid induced inhibition of
[3H]GABA evoked release.
The triggering of a metabotropic action by kainate receptor
activation to inhibit [3H]GABA evoked release was further
investigated by testing the e¡ect of protein kinase inhibition
on kainate receptor-mediated inhibition of [3H]GABA evoked
release. As illustrated in Fig. 2A, the Ca2-calmodulin kinase
II inhibitor KN-62 (1 WM, n = 3) or the mitogen-activated
protein kinase kinase inhibitor PD 98059 (50 WM, n = 3) failed
to signi¢cantly (Ps 0.05) modify the domoate (3 WM)-induced
inhibition of [3H]GABA evoked release (Fig. 2A), suggesting
a lack of direct involvement of these two transducing systems.
In contrast, the inhibition by domoate (3 WM) of [3H]GABA-
evoked release was attenuated by 82 þ 8% by the protein ki-
nase C inhibitor, chelerythrine (6 WM, n = 4) (Fig. 2B). Fur-
thermore, supramaximal activation of hippocampal protein
kinase C activity with 250 nM phorbol-12,13-didecanoate
(see [11]) also prevented the domoate induced GABA inhibi-
tion (n = 3) (Fig. 2B), whereas its inactive analogue, 4K-phor-
bol-12,13-didecanoate (250 nM, n = 2) was devoid of e¡ects
(Fig. 2B). This con¢rms the previous suggestion of the in-
volvement of protein kinase C on the presynaptic modulation
of GABA release (see [3]). The inhibition by domoate (3 WM)
of [3H]GABA evoked release was also inhibited by 26 þ 4% by
the protein kinase A inhibitor HA-1004 (10 WM, n = 4) (Fig.
2A). However, the more selective protein kinase A inhibitor,
H-89 (1 WM, n = 2, or 3 WM, n = 2) did not modify the do-
moate (3 WM)-induced inhibition of GABA release (Fig. 2A).
This suggests that the protein kinase A pathway is not re-
cruited by kainate receptors, as reported by others [3], and
the e¡ect of HA-1004 might be due to its ability to inhibit
protein kinase C due to its low protein kinase A versus C
selectivity [13].
Kainate receptor function has previously been shown to be
controlled by protein kinases, namely by protein kinase A
(e.g. [14]). Therefore, it is important to distinguish if protein
kinases are triggered by kainate receptor activation or if pro-
tein kinases are controlling kainate receptor function. To in-
vestigate this issue, we tested the ability of the membrane-
permeable protein kinase A activator, 8-bromo-cAMP
(1 mM) and of the protein kinase C activator phorbol-
12,13-didecanoate (250 nM) to modify binding to kainate re-
ceptors. The pre-treatment of hippocampal synaptosomes for
15 min with the protein kinase C activator failed to signi¢-
cantly (Ps 0.05) modify [3H]MGA saturation curve to mem-
branes prepared from these synaptosomes when compared to
control (Fig. 2B), which contrasts with the reduction in KD
caused by PTx [10]. However, activation of protein kinase A
lead to a reduction in the binding of the higher concentrations
of [3H]MGA (Fig. 2B), although the changes in KD and BMAX
did not reach statistical signi¢cance (Ps 0.05). Thus, the
present results support the view that protein kinase C may
be part of the transducing pathway of kainate receptor-medi-
ated inhibition of GABA release rather than directly regulat-
ing kainate receptor function. In contrast, protein kinase A is
not part of the transducing system operated by kainate recep-
Fig. 2. Ability of inhibitors and activators of protein kinases to af-
fect the kainate receptor-mediated inhibition of GABA evoked re-
lease from rat hippocampal nerve terminals (A and B) and
[3H]MGA-binding to rat hippocampal synaptosomal membranes
(C). In (A) and (B), the protein kinase inhibitors were added 15
min before starting sample collection, i.e. they were present both
during S1 and S2, whereas domoate was added 6 min before S2 on-
wards. The results are mean þ S.E.M. of 3^4 experiments, except for
4K-phorbol-12,13-didecanoate which is n = 2. *P6 0.05 versus 0%;
**P6 0.05 versus the inhibitory e¡ect of domoate (3 WM) (¢rst col-
umn). In (C) the average saturation curves are shown of [3H]MGA-
binding to rat hippocampal synaptosomal membranes upon pre-
treatment of the synaptosomes in the absence of drugs (circles) or
in the presence of the protein kinase A activator, 8-bromo-cAMP (1
mM, ¢lled squares), or of the protein kinase C activator, phorbol-
12,13-didecanoate (250 nM, black and white arrowheads) for 15
min at 37‡C. The ordinates represent the speci¢c binding of
[3H]MGA on subtraction of the non-speci¢c binding, determined in
the presence of 100 WM kainate from total binding. Results are
mean þ S.E.M. of three experiments performed in duplicate. The KD
values were 33 nM (95% con¢dence interval: 22^44 nM) in control
conditions, 48 nM (30^66 nM) upon 8-bromo-cAMP pre-treatment
and 39 nM (27^60 nM) upon phorbol-12,13-didecanoate pre-treat-
ment. The Bmax values were 2250 þ 132 fmol/mg protein in control
conditions, 2071 þ 53 fmol/mg protein upon 8-bromo-cAMP pre-
treatment and 2182 þ 54 fmol/mg protein upon phorbol-12,13-dide-
canoate pre-treatment.
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tors to inhibit GABA release but may directly regulate kainate
receptor function in the hippocampus.
The present results demonstrate that kainate receptor acti-
vation requires functional Gi/Go proteins to inhibit GABA
release from hippocampal nerve terminals, con¢rming pre-
vious electrophysiological data indicating a PTx-sensitive kai-
nate receptor inhibition of GABAergic transmission in hippo-
campal CA1 area [3]. The qualitative similarity of PTx
sensitivity of this direct presynaptic e¡ect of kainate receptor
activation on GABA release and on GABAergic transmission
is suggestive of a main presynaptic locus of kainate receptor
action in the control of GABAergic function in the hippo-
campus. Like presynaptic kainate receptors, postsynaptic
AMPA receptors can also signal through G proteins (e.g.
[15]). However, it is still not clear if these ionotropic gluta-
mate receptors directly couple to Gi/Go proteins or more
likely indirectly couple to G proteins via ancillary proteins
(e.g. [16]). Also, the metabolic route operated by presynaptic
kainate receptors downstream of Gi/Go proteins remains to be
determined, but appears to be di¡erent from that triggered by
postsynaptic AMPA receptors (see [15]).
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